Tatsuki Ikoma

12PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersMolecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Mar 15, 2026
Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab.

Shogen Boku, Masato Kita, Tatsuki Ikoma

|Jan 28, 2026
Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology.

Satoshi Ikeda, Keigo Araki, Mai Kitagawa

|Jul 10, 2025
Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck.

Shogen Boku, Tatsuki Ikoma, Tomoyo Yasuda

|Jul 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.

Tae Hata, Tadaaki Yamada, Yasuhiro Goto

|May 19, 2025
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.

Shiho Goda, Tadaaki Yamada, Kenji Morimoto

|Dec 19, 2024
Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real-World Evidence.

Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako

Pageof 2

Frequent Collaborators

4 joint publications

Shogen Boku

4 joint publications

Nobuhiro Shibata

3 joint publications

Toshihiko Matsumoto

3 joint publications

Hironaga Satake